FILE:BSX/BSX-8K-20040202083629.txt.gz
EVENTS:	
TEXT:
ITEM: 
================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ---------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 2, 2004 BOSTON SCIENTIFIC CORPORATION ----------------------------- (Exact name of registrant as specified in charter) DELAWARE 1-11083 04-2695240 - --------------- ----------- ------------- (State or other (Commission (IRS employer jurisdiction of file number) identification no.) incorporation) ONE BOSTON SCIENTIFIC PLACE, NATICK, MASSACHUSETTS 01760-1537 -------------------------------------------------- ---------- (Address of principal executive offices) (Zip code) Registrant's telephone number, including area code: (508) 650-8000 ================================================================================
ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On February 2, 2004, Boston Scientific Corporation (the "Company") issued a press release announcing financial results for the fourth quarter and for the year ended December 31, 2003. A copy of the release is furnished with this report as Exhibit 99.1. The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BOSTON SCIENTIFIC CORPORATION Date: February 2, 2004 By: /s/ Lawrence J. Knopf -------------------------------------------- Lawrence J. Knopf Vice President and Assistant General Counsel

EXHIBIT 99.1 ------------ NEWS [LOGO] FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC Boston Scientific Corporation One Boston Scientific Place Natick, MA 01760-1537 508.650.8000 www.bostonscientific.com BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2003 Natick, MA (February 2, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for the fourth quarter and for the year ended December 31, 2003. The results reported today are consistent with the preliminary results reported on January 13. FOURTH QUARTER 2003 - ------------------- Net sales for the fourth quarter of 2003 were $939 million as compared to $814 million for the fourth quarter of 2002, an increase of 15 percent. Excluding the favorable impact of $57 million of foreign currency fluctuations, net sales were $882 million. Net income for the quarter, excluding net special charges, was $141 million, or $0.17 per share (diluted), as compared to $130 million, excluding net special charges, or $0.15 per share in the fourth quarter of 2002. Reported net income for the quarter, including net special charges of $4 million, was $137 million, or $0.16 per share, as compared to reported net income of $105 million, or $0.12 per share, in the fourth quarter of 2002. (The earnings per share figures reported in this press release reflect the Company's two-for-one common stock split that became effective in November of 2003.) YEAR-END 2003 - ------------- Net sales for the year ended December 31, 2003 were $3.476 billion as compared to $2.919 billion in 2002, an increase of 19 percent. Excluding the favorable impact of $162 million of foreign currency fluctuations, net sales were $3.314 billion. Net income for the year, excluding net special charges, increased 26 percent to $521 million, or $0.62 per share, as compared to $413 million, excluding net special charges, or $0.50 per share for the year ended December 31, 2002. Reported net income for the year, including net special charges of $49 million, was $472 million or $0.56 per share, as compared to reported net income of $373 million or $0.45 per share for the prior year. "We further strengthened our market leadership position in drug-eluting stents in Europe and other international markets during the fourth quarter," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "Our impressive performance in these markets gives us further confidence as we prepare to launch our TAXUS(TM) paclitaxel-eluting stent system in the United States later this quarter." -- more --
Boston Scientific Corporation/Page 2 February 2, 2004 Boston Scientific officials will be discussing these and other issues with analysts on a conference call at 9:00 a.m. (ET) on Monday, February 2. The Company will webcast the call to all interested parties through its website www.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for 10 business days on the Boston Scientific website. The Company plans to hold an analyst meeting in New York on February 23. The Company will webcast the meeting to all interested parties through its website: www.bostonscientific.com. Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com. The Company discloses non-GAAP or pro forma financial information that excludes certain items. Non-GAAP financial information may exclude such items as charges related to purchased in-process research and development and certain litigation. Management uses this financial information to establish operational goals, and believes that non-GAAP financial information may assist investors in analyzing the underlying trends in the Company's business over time. Investors should consider this non-GAAP financial information in addition to, not as a substitute for, or as superior to, financial information prepared in accordance with GAAP. This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and introduction, clinical trials, regulatory approvals, competitive offerings, intellectual property, litigation, operational improvements, the Company's overall business strategy, and other factors described in the Company's filings with the Securities and Exchange Commission. CONTACT: Milan Kofol 508-650-8569 Investor Relations Boston Scientific Corporation Paul Donovan 508-650-8541 Media Relations Boston Scientific Corporation
BOSTON SCIENTIFIC CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
BOSTON SCIENTIFIC CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
BOSTON SCIENTIFIC CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
BOSTON SCIENTIFIC CORPORATION WORLDWIDE SALES REGIONAL SUMMARY (Unaudited) 1 Certain prior year's amounts have been reclassified to conform to the current year's presentation.
BOSTON SCIENTIFIC CORPORATION WORLDWIDE SALES DIVISIONAL SUMMARY (Unaudited) 1 Certain prior year's amounts have been reclassified to conform to the current year's presentation.


